ArticleBritish journal of cancer2025

Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.

Kaiqi Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.